Design Therapeutics, Inc. (DSGN): Price and Financial Metrics
DSGN Price/Volume Stats
| Current price | $5.84 | 52-week high | $6.91 |
| Prev. close | $5.22 | 52-week low | $1.96 |
| Day low | $5.35 | Volume | 376,900 |
| Day high | $6.01 | Avg. volume | 257,697 |
| 50-day MA | $4.56 | Dividend yield | N/A |
| 200-day MA | $3.51 | Market Cap | 329.93M |
DSGN Stock Price Chart Interactive Chart >
Design Therapeutics, Inc. (DSGN) Company Bio
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
Latest DSGN News From Around the Web
Below are the latest news stories about DESIGN THERAPEUTICS INC that investors may wish to consider to help them evaluate DSGN as an investment opportunity.
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should KnowDesign Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Positive Signs As Multiple Insiders Buy Design Therapeutics StockUsually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like... |
Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic UpdatePratik Shah Takes Helm as CEO, Company Eyes Long-Term Growth |
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term Growth to be Presented in Early 2024; Additional Details to Follow CARLSBAD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic |
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
DSGN Price Returns
| 1-mo | 38.39% |
| 3-mo | 57.41% |
| 6-mo | 126.36% |
| 1-year | 117.91% |
| 3-year | -63.88% |
| 5-year | N/A |
| YTD | 120.38% |
| 2023 | -74.17% |
| 2022 | -52.08% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...